Advertisement

Reduction of a distinct pool of monoamines by ketanserin in peripheral tissues

  • J. E. Leysen
  • J. Wynants
  • A. Eens
  • P. A. J. Janssen
Chapter
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)

Abstract

Ketanserin is a prototype of a 5-HT2 antagonist which also has moderate α1-adrenoceptor blocking properties. These properties are thought to underly its demonstrated antithrombotic and antivasoconstrictive activities (for reviews see [1, 2]).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Van Nueten JM, Janssen, HAJ, Symoens J, Janssens WJ, Heykants J, De Clerck F, Leysen JE, Vancauteren H, Vanhoutte PM (1987): Ketanserin, pp. 1–56 in: Scriabine A (ed), New Cardiovascular Drugs. New York: Raven Press.Google Scholar
  2. 2.
    Vanhoutte PM, Ball SG, Berdeaux A, Cohen ML, Hedner T, McCall R, Ramage A, Reimann IH, Richer C, Saxena PR, Schalekamp MADH, Struyker-Boudier HAJ, Symoens J, Van Nueten JM, Van Zwieten PA (1986): Mechanism of action of ketanserin in hypertension. Trends PharmacolSci 7: 58 – 59.CrossRefGoogle Scholar
  3. 3.
    Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982): [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Mol Pharmacol 21: 301–314.PubMedGoogle Scholar
  4. 4.
    Pletscher A, Brossi A, Gey KF (1962): Benzoquinolizine derivates: a new class of monoamine decreasing drugs with psychotropic action. Int Rev Neurobiol4: 275–306.CrossRefGoogle Scholar
  5. 5.
    Leysen JE, Eens A, Gommeren W, Van Gompel P, Wynants J, Janssen PAJ (1987): Non-serotonergic [3H] ketanserin binding sites in striatal membranes are associated with a dopac release system on dopaminergic nerve endings. Eur J Pharmacol134: 373–375.PubMedCrossRefGoogle Scholar
  6. 6.
    Leysen JE, Eens A, Gommeren W, Van Gompel P, Wynants J, Janssen PAJ (1988): Identification of nonserotonergic [3H] ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs. J Pharmacol Exp Ther244: 310–321.PubMedGoogle Scholar
  7. 7.
    Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PFM, Laduron PM (1985): Receptor-binding properties in vitro and in vivo of ritanserin. A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol27: 600–611.PubMedGoogle Scholar
  8. 8.
    Darchen F, Scherman D, Laduron PM, Henry J-P (1988): Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol Pharmacol33: 672–677.PubMedGoogle Scholar
  9. 9.
    De Cree J, Leempoels J, Geukens H, De Cock W, Verhaegen H (1981): The antihypertensive effects of ketanserin (R 41 468), a novel 5-hydroxytryptamine-blocking agent, in patients with essential hypertension. Clin Sci 61:473s–476s.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • J. E. Leysen
  • J. Wynants
  • A. Eens
  • P. A. J. Janssen

There are no affiliations available

Personalised recommendations